Welcome to our dedicated page for Civeo SEC filings (Ticker: CVEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Civeo's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Civeo's regulatory disclosures and financial reporting.
BLANKENSHIP C RONALD reported acquisition or exercise transactions in this Form 4 filing.
Civeo Corp director C. Ronald Blankenship received a grant of 3,624 restricted common shares as equity compensation. The award carries no purchase price and was granted under the Amended and Restated 2014 Equity Participation Plan of Civeo Corporation. According to the footnote, these restricted shares vest on the earlier of one year from May 27, 2026 or the next annual shareholders' meeting date. Following this award, Blankenship directly holds 54,446 common shares.
Scofield Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
Civeo Corp director Jeffrey Scofield received a grant of 3,624 Common Shares as a restricted common share award. The award was granted at a price of $0.00 per share under Civeo’s Amended and Restated 2014 Equity Participation Plan.
According to the award terms, these restricted common shares vest on the earlier of one year from May 27, 2026 or the date of the next annual shareholders' meeting. After this grant, Scofield directly holds a total of 9,242 Common Shares.
Silvers Daniel B. reported acquisition or exercise transactions in this Form 4 filing.
Civeo Corp director Daniel B. Silvers received a grant of 3,624 deferred shares of the company. These shares were awarded at a stated price of $0.00 per share as equity compensation. The award was made under Civeo’s Amended and Restated 2014 Equity Participation Plan.
According to the terms, the deferred shares vest on the earlier of one year from May 27, 2026 or the next annual shareholders' meeting date. Following this award, Silvers holds 3,624 deferred shares directly.
Wall Timothy O reported acquisition or exercise transactions in this Form 4 filing.
Civeo Corp director Timothy O. Wall received a grant of 3,624 common shares as equity compensation. The award is a restricted common share grant under the Amended and Restated 2014 Equity Participation Plan of Civeo Corporation and carries no cash purchase price. These restricted shares vest on the earlier of one year from May 27, 2026 or the next annual shareholders' meeting date. Following this award, Wall directly holds a total of 21,813 common shares.
LAMBERT MARTIN reported acquisition or exercise transactions in this Form 4 filing.
Civeo Corp director Martin Lambert reported receiving a grant of 3,624 restricted common shares of Civeo Corporation at no purchase price under the Amended and Restated 2014 Equity Participation Plan. These shares vest on the earlier of one year from May 27, 2026 or the next annual shareholders' meeting date. Following this award, Lambert directly holds 40,060 common shares.
MOORE CONSTANCE B reported acquisition or exercise transactions in this Form 4 filing.
Civeo Corp director Constance B. Moore received a grant of 3,624 common shares as a restricted share award. The award was granted at a stated price of $0 per share under Civeo’s Amended and Restated 2014 Equity Participation Plan, increasing her direct holdings to 49,983 common shares.
The restricted common share award will vest on the earlier of one year from May 27, 2026 or the date of Civeo’s next annual shareholders’ meeting, linking the compensation to continued board service over that period.
Montelongo Michael reported acquisition or exercise transactions in this Form 4 filing.
Civeo Corp director Michael Montelongo received a grant of 3,624 Deferred Shares as equity compensation. The award was made at a stated price of $0.00 per share and increased his directly held Deferred Shares to 25,522 following the transaction. According to the accompanying note, the Deferred Shares were granted under Civeo’s Amended and Restated 2014 Equity Participation Plan and vest on the earlier of one year from May 27, 2026 or the next annual shareholders' meeting date.
Civeo Corporation reported the results of its 2026 Annual General Meeting of Shareholders. Shareholders elected six directors across Class II and Class III, with each nominee receiving more than 8.29 million votes in favor.
They also approved, on an advisory basis, the compensation of the named executive officers and approved an amendment to the 2014 Equity Participation Plan to increase the number of shares available for issuance by 520,920 shares, subject to adjustment under the plan. In addition, shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Civeo Corporation reports first-quarter 2026 results with higher revenue but a smaller net loss than a year ago. Revenue rose to $172.7 million from $144.0 million, driven by growth in both Australia and Canada, including contributions from the Qantac acquisition and stronger demand at Canadian oil sands lodges.
Net loss attributable to Civeo narrowed to $3.8 million, or $0.34 per share, from $9.8 million, or $0.72 per share. Operating income improved to $3.1 million versus a loss previously as cost reductions and higher Canadian occupancy expanded margins. Civeo used $9.7 million of cash in operations, spent $4.1 million on capital expenditures, repurchased 511,000 shares for $14.4 million, and ended the quarter with $68.4 million of total available liquidity and $212.3 million of debt. The company also extended and upsized its revolving credit facility in April 2026.
Civeo Corporation reported a Schedule 13G identifying American Century entities and Stowers Institute as beneficial owners of 561,834 shares of Common Stock, representing 5.1% of the class. The filing states sole voting and dispositive power over the reported shares for the named filers and is dated May 1, 2026.